Oxyrane is focused on development of novel enzyme therapies for the treatment of severe lysosomal storage disorders, including Gaucher, Pompe and Parkinson's disease. Oxyrane has developed a proprietary platform for the production of enzymes with enhanced phosphorylation of the sugar structures on the surface. This system generates enzymes with very high cellular uptake and subcellular targeting, potentially allowing for a superior efficacy at lower doses of enzyme therapies. Oxyrane is a private company with operations in Manchester, UK and Gent, Belgium. It is backed by top-tier venture capital investors, New Science Ventures (New York) and Forbion Capital Partners (the Netherlands), and supported by a board with renowned leaders in the development of innovative therapies - Philip Astley-Sparke, Leonard Post, Charles Richard, Hans Preusting, Sander Slootweg and Somu Subramaniam.
| Website | http://www.oxyrane.com |
| Revenue | $7 million |
| Employees | View employees |
| Address | 49 Piccadilly, Manchester, England M1 2AP, GB |
| Phone | +44 161 232 6000 |
| Industry | Business Services General, Business Services |
| Competitors | AQWEST, LLC, Xylem, Veolia, SUEZ, ADI® Systems, an Evoqua brand, Aquatech, Pentair, GE, Mwh Construction, BASF +38 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 541714 Companies |
Looking for a particular Oxyrane , Ltd. employee's phone or email?
Oxyrane , Ltd. Questions
The Oxyrane , Ltd. annual revenue was $7 million in 2026.
Oxyrane , Ltd. is based in Manchester, England.
The NAICS codes for Oxyrane , Ltd. are [54, 54171, 5417, 541, 541714].
The SIC codes for Oxyrane , Ltd. are [873, 87].
